Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16380066 | 1.00 | PAK4 (0.45) | PAK4HRH3NAMPTPAK1NTRK1 | |
| SCHEMBL18325823 | 0.91 | PAK4 (0.46) | PAK4HRH3NAMPTPAK1GABRA5 | |
| SCHEMBL16345330 | 0.89 | PAK4 (0.46) | PAK4HRH3NAMPTPAK1RORC | |
| SCHEMBL16379571 | 0.86 | PAK4 (0.44) | PAK4HRH3NAMPTPAK1NTRK1 | |
| SCHEMBL18328792 | 0.86 | PAK4 (0.53) | PAK4HRH3NAMPTPAK1NTRK1 | |
| SCHEMBL29999991 | 0.85 | PAK4 (0.42) | PAK4HRH3NAMPTPAK1GABRA5 | |
| SCHEMBL16379652 | 0.85 | PAK4 (0.42) | PAK4HRH3NAMPTPAK1GABRA5 | |
| SCHEMBL16379978 | 0.85 | PAK4 (0.52) | PAK4HRH3NAMPTPAK1GABRA5 | |
| SCHEMBL16346356 | 0.84 | HRH3 (0.42) | PAK4HRH3NAMPTPAK1GABRA5 | |
| SCHEMBL29611400 | 0.84 | HRH3 (0.42) | PAK4HRH3NAMPTPAK1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3016946-B1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PAK4 2260/4885HRH3 4681/4885NAMPT 1782/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | PAK4 4159/4885HRH3 3370/4885NAMPT 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.